Robert W. Duggan - Dec 4, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Director, 10%+ Owner
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Dec 4, 2023
Transactions value $
$710,359
Form type
4
Date filed
12/6/2023, 07:54 PM
Previous filing
Dec 5, 2023
Next filing
Dec 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Options Exercise $213K +20K +0.05% $10.66 36.6M Dec 4, 2023 Direct
transaction PLSE Common Stock Options Exercise $217K +20.3K +0.06% $10.66 36.6M Dec 4, 2023 Direct
transaction PLSE Common Stock Purchase $280K +27K +10.44% $10.38 286K Dec 4, 2023 See footnote F1, F2
holding PLSE Common Stock 492K Dec 4, 2023 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Options Exercise $0 -20K -100% $0.00* 0 Dec 4, 2023 Common Stock 20K $10.66 Direct F4
transaction PLSE Stock Option (right to buy) Options Exercise $0 -20.3K -100% $0.00* 0 Dec 4, 2023 Common Stock 20.3K $10.66 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Volume-weighted average price.
F2 Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
F3 Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
F4 Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2020 Annual Stockholder Meeting.
F5 Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quarterly basis following the Company's 2020 Annual Stockholder Meeting.